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Brief Definit ive Report
Microglia reactivity to amyloid- (A) plaques 
is a key feature of Alzheimer’s disease (AD) pa-
thology, but the exact nature of this cellular 
immune response and impact on disease patho-
genesis and progression is still far from clear 
(Prokop et al., 2013). During the progression of 
A pathology in AD-like mouse models, mi-
croglia exhibit a reduction in cellular functions 
like phagocytosis and response to injury (Krabbe 
et al., 2013), and depletion of microglia for up 
to 30 d in two mouse models of AD had no 
major impact on development or progression 
of A pathology (Grathwohl et al., 2009), sug-
gesting that microglia are inefficient at manag-
ing the increasing A load. In contrast, there 
are examples in which modulation of the mi-
croglia response toward A did have a major 
impact on disease progression (vom Berg et al., 
2012; Heneka et al., 2013; Chakrabarty et al., 
2015; Guillot-Sestier et al., 2015). Further com-
plicating the quest for understanding the role 
of microglia in AD is the fact that peripheral 
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Although central nervous system–resident microglia are believed to be ineffective at 
phagocytosing and clearing amyloid- (A), a major pathological hallmark of Alzheimer’s 
disease (AD), it has been suggested that peripheral myeloid cells constitute a heteroge-
neous cell population with greater A-clearing capabilities. Here, we demonstrate that 
the conditional ablation of resident microglia in CD11b-HSVTK (TK) mice is followed by a 
rapid repopulation of the brain by peripherally derived myeloid cells. We used this system 
to directly assess the ability of peripheral macrophages to reduce A plaque pathology 
and therefore depleted and replaced the pool of resident microglia with peripherally 
derived myeloid cells in A-carrying APPPS1 mice crossed to TK mice (APPPS1;TK). 
Despite a nearly complete exchange of resident microglia with peripheral myeloid cells, 
there was no significant change in A burden or APP processing in APPPS1;TK mice. 
Importantly, however, newly recruited peripheral myeloid cells failed to cluster around 
A deposits. Even additional anti-A antibody treatment aimed at engaging myeloid 
cells with amyloid plaques neither directed peripherally derived myeloid cells to amyloid 
plaques nor altered A burden. These data demonstrate that mere recruitment of periph-
eral myeloid cells to the brain is insufficient in substantially clearing A burden and 
suggest that specific additional triggers appear to be required to exploit the full poten-
tial of myeloid cell–based therapies for AD.
© 2015 Prokop et al. This article is distributed under the terms of an Attribution– 
Noncommercial–Share Alike–No Mirror Sites license for the first six months 
after the publication date (see http://www.rupress.org/terms). After six months 
it is available under a Creative Commons License (Attribution–Noncommercial– 
Share Alike 3.0 Unported license, as described at http://creativecommons.org/ 
licenses/by-nc-sa/3.0/).
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that exchanging the microglia population with peripheral 
macrophages fails to reduce A pathology and, importantly, 
that infiltrating myeloid cells show no targeted response to 
A plaques.
RESULTS AND DISCUSSION
Peripheral origin of CNS-repopulating myeloid cells  
in microglia-depleted CD11b-HSVTK (TK) mice
To demonstrate the origin of the cells repopulating the 
microglia-depleted brain in TK mice (Varvel et al., 2012) 
without the bias and side effects of bone marrow chimerism, 
we performed isochronic parabiosis experiments, in which TK 
mice were paired with Actin.enhanced green fluorescent pro-
tein (Act.GFP) partners (for experimental details see Fig. 1). 
After successful establishment of a joined blood compart-
ment, demonstrated by a blood chimerism of 40% (Fig. 1 c), 
we achieved the exchange of resident microglia in the TK 
myeloid cells can enter the central nervous system (CNS) 
under certain conditions (Ajami et al., 2007; Mildner et al., 
2011) and contribute to the immune response toward A de-
posits (Stalder et al., 2005). The notion that newly recruited 
myeloid cells may be better effector cells than the dysfunc-
tional resident microglia to combat A deposits has been sup-
ported by studies claiming or demonstrating that reduced 
recruitment of myeloid cells enhances AD-like pathology 
(Simard et al., 2006; Mildner et al., 2011; Naert and Rivest, 
2011) and, similarly, that enhanced recruitment of myeloid 
cells can be beneficial for the clearance of A pathology 
(Town et al., 2008). To directly test the hypothesis that 
peripheral myeloid cells are better A-combatting cells than 
resident microglia, we used an experimental mouse model 
that allows for the exchange of resident microglia by periph-
erally derived myeloid cells upon conditional depletion of 
these CNS-resident cells (Varvel et al., 2012). Our data reveal 
Figure 1. Peripheral origin of repopulating myeloid cells in nonchimeric microglia-depleted parabiotic mice. TK and Act.GFP mice were surgically 
connected to establish a joined circulatory system. Upon establishment of blood chimerism in both partners (2 wk), icv GCV was administered to the TK part-
ners for 10 d to deplete microglia. Mice were sacrificed 24 d after starting GCV treatment. (a and b) Representative images of GFP-positive cells (middle col-
umns) in microglia-depleted (GCV-treated) TK mice (bottom rows), WT controls (top rows), or non-microglia–depleted aCSF-treated TK controls (middle rows). 
Shown are cortical (a) or hippocampal (b) brain regions stained for Iba1 (left columns) or GFP (middle columns), as well as merged images (right columns). 
Bars, 200 µm. (c) Flow cytometric analysis of GFP+ cells in blood of parabiotic pairs. (d and e) Stereological quantification of Iba1-positive cells (d; *, P = 0.03; 
n = 5 per group) and GFP-positive cells (e; *, P = 0.02; n = 5 per group) in brains of mice described in a–c. All data are displayed as mean ± SEM.
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equivalent numbers of stereologically quantified Iba1-positive 
cells in repopulated, APPPS1;TK+/and nonrepopulated, 
APPPS1;TK/ mice (Fig. 2 b). Interestingly, Trem2, a gene 
recently identified as a risk factor for AD (Guerreiro et al., 
2013; Jonsson et al., 2013), also remained unchanged upon 
peripheral macrophage infiltration, suggesting that both resi-
dent microglia and peripheral myeloid cells can contribute to 
TREM2 protein expression in the brain, an issue which has 
been discussed controversially (Frank et al., 2008; Ulrich et al., 
2014; Jay et al., 2015).
Unaltered A pathology in the presence of peripherally 
derived myeloid cells
Surprisingly, the exchange of endogenous microglia with pe-
ripheral myeloid cells did not affect cerebral amyloid pathol-
ogy, as judged by stereological quantification of A plaque 
burden (Fig. 2, e and f ). Similarly, the amount of Congo red–
positive plaques was also not altered in the presence of 
peripheral macrophages (Fig. 2, g and h). In line with these 
findings, biochemical analyses revealed unchanged levels of 
soluble and insoluble as well as total A species (Fig. 2 i) in 
brains of APPPS1;TK+/ mice harboring peripheral myeloid 
cells when compared with APPPS1;TK/ mouse brains 
comprising resident microglia. Finally, there was also no major 
effect on APP processing, as judged by assessing the amounts 
of APP, APPCTF, and APPCTF (CTF, C-terminal fragment) 
by means of Western blotting (Fig. 2 j). Although it was unex-
pected that the exchange of endogenous microglia with 
large numbers of peripheral myeloid cells had no effect on A 
pathology, this result is less surprising given the failure of in-
filtrating macrophages to associate with A plaques (Fig. 2 c). 
Given that astrocytes are present in this model and capable 
of producing chemokines (Liu et al., 2014), along with some 
remaining endogenous microglia, this lack of attraction to 
plaques by peripherally derived myeloid cells may be because 
A plaques do not represent a sufficient or appropriate innate 
immune-activating stimulus. However, this question deserves 
further investigation in future experiments.
Passive A vaccination is insufficient to direct peripherally 
derived myeloid cells to amyloid plaques
To provide a more stringent setting in which to test the A-
clearing abilities of infiltrating myeloid cells, we sought to 
actively recruit the cells toward the A plaques by treating 
animals with the anti-A antibody Ab9 upon myeloid cell 
repopulation (Levites et al., 2006), which has been shown 
to direct the myeloid cell response toward amyloid deposits 
(Wang et al., 2011). After microglia depletion in APPPS1;TK+/ 
mice and identical treatment of respective APPPS1;TK/ 
control mice, GCV administration was stopped. During a 
subsequent 4-wk time period in which the newly recruited 
peripheral myeloid cells were present in the brain, mice re-
ceived a series of six intraperitoneal injections of Ab9 or re-
spective isotype control antibodies; the former regimen has 
been found to confer a reduction in amyloid burden in A-
carrying mice (not depicted). Again, we observed similar 
transgene–expressing partner by intracerebroventricular (icv) 
application of ganciclovir (GCV) for 10 d, followed by 2 wk 
of no treatment (Fig. 1). Although the application of GCV 
into wild-type control mice and the application of artificial 
cerebrospinal fluid (aCSF) in TK mice did not lead to a signif-
icant influx of GFP-positive peripheral myeloid cells into the 
brain (Fig. 1, a, b, and e), in TK mice treated with GCV (re-
sulting in depletion of endogenous microglia) we observed a 
robust increase in Iba1-positive cells (Fig. 1 d), as described 
previously (Varvel et al., 2012). Consistent with the degree 
of chimerism, a substantial percentage of the CNS-infiltrating 
cells were GFP positive (Fig. 1, a, b, and e), indicating their pe-
ripheral origin, and were observed evenly distributed through-
out the parenchyma (Fig. 1, a and b). These data demonstrate 
that in the TK mouse model, depletion of resident microglia 
is followed by a rapid repopulation by peripherally derived 
myeloid cells in the absence of additional stimuli, such as bone 
marrow chimerism or whole brain irradiation.
No recruitment of peripherally derived myeloid cells  
to A plaques
To exchange the resident microglia pool with peripheral my-
eloid cells in an A-carrying AD-like mouse model, we gen-
erated APPPS1;TK+/ mice by crossing APPPS1 (Radde 
et al., 2006) to TK mice (Heppner et al., 2005). 28 d after a 
10-d GCV regimen to deplete endogenous microglia, we 
observed a repopulation of the microglia niche by Iba1-positive 
cells in APPPS1;TK+/ mice (Fig. 2 a). The newly recruited 
myeloid cells in APPPS1;TK+/ mice were present at num-
bers comparable with the endogenous microglia cells in 
similarly GCV-treated APPPS1;TK/ mice (Fig. 2 b) and 
untreated APPPS1 mice (not depicted). In addition, these 
cells exhibited a distinct morphology characterized by broader, 
more rod-shaped cell bodies than the ramified resident mi-
croglia (Fig. 2 a). Furthermore, the newly repopulating cells 
were evenly distributed throughout the tissue, as has been 
previously described for the repopulation paradigm in the 
non-AD context (Varvel et al., 2012). Strikingly, however, 
the obvious clustering of resident microglia around A de-
posits normally observed in the AD brain and AD mouse 
models, including the nonrepopulated APPPS1;TK/ con-
trol mice used in this study, was not apparent in APPPS1;TK+/ 
mice harboring peripheral myeloid cells in the brain (Fig. 2 c), 
suggesting that A plaques serve as an insufficient stimulus 
to induce a targeted response by infiltrating macrophages. 
Quantitative PCR (qPCR) analysis of RNA isolated from 
cerebral hemispheres of APPPS1;TK+/ and APPPS1;TK/ 
mice revealed a significant down-regulation of the gene hex-
osaminidase B (Hexb) and the purinergic receptor P2ry12 
(Fig. 2 d), both of which have been shown to be significantly 
enriched in CNS-resident microglia compared with periph-
eral macrophages (Hickman et al., 2013), thus confirming the 
successful depletion of resident microglia and replacement 
by peripheral myeloid cells. In contrast, the common mi-
croglia and macrophage genes CD11b and Cx3cr1 remained 
unchanged (Fig. 2 d), which is well in line with detecting 
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Figure 2. Peripheral myeloid cells do not affect A pathology in microglia-depleted APPPS1;TK+/ mice. (a) Representative images of Iba1 
immunohistochemistry (blue) in peripheral myeloid cell–repopulated APPPS1;TK+/ mice (bottom) and similarly GCV-treated APPPS1;TK/ control mice 
(top). (b) Stereological quantification of Iba1-positive cells (n = 5–8 per group). (c) Overview images of Iba1 immunohistochemistry (blue). (d) qPCR analy-
sis of Cd11b, Cx3cr1, Hexb, P2ry12, and Trem2 from whole brain tissue of APPPS1;TK+/ mice compared with APPPS1;TK/ controls (*, P = 0.03;  
**, P = 0.007; n = 6 per group). (e) Representative images of 4G8 immunohistochemistry. (f) Stereological quantification of the area covered by 4G8- 
positive plaques (n = 6–9 per group). (g and h) Congo red staining (g) and stereological quantification (h) of the area covered by Congo red–positive 
plaques (n = 6–9 per group). Bars: (a) 20 µm; (c, e, and g) 100 µm. (i) Amount of soluble and insoluble A40 and A42 and total A40 and A42 calcu-
lated from individual fractions measured by Meso Scale Diagnostics (measurements performed in duplicate from n = 5 biological replicates per group).  
(j) Representative Western blot images of APP, APPCTF, and APPCTF in SDS fractions from brain homogenates described in i (6E10 detection; left) and 
representative quantification of Western blots (right; result representative for four independent experiments). All p-values >0.05 unless otherwise stated. 
All data are represented as mean ± SEM. All mice were treated icv for 10 d with GCV followed by a 28-d period without GCV administration.
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Figure 3. Anti-A antibodies fail to specifically promote plaque association or clearance by peripheral myeloid cells. (a) Representative images of 
Iba1 immunohistochemistry (blue) combined with pFTAA staining (green) are shown. (b) Stereological quantification of number of Iba1-positive cells (left; 
n = 5–6 per group) and quantification of Iba1-positive cell bodies per pFTAA area (right; n = 5–6 per group; ***, P = 0.0005). (c and e) Representative images 
of 4G8 immunohistochemistry (c) and Congo red staining (e). (a, c, and e) Bars, 100 µm. (d) Stereological quantification of the area covered by 4G8-positive 
plaques (top; **, P = 0.009) and number of 4G8-positive plaques (bottom; *, P = 0.02; n = 5–7 per group). (f) Stereological quantification of the number of 
Congo red–positive plaques (*, P = 0.02; n = 5–7 per group). (g) Amount of soluble and insoluble A40 and A42 and total A40 and A42 calculated from 
individual protein fractions (*, P = 0.04; measurements performed in duplicate from n = 5–7 biological replicates per group). (h) Representative image of 
Western blot analyses of APP, APPCTF, and APPCTF in SDS-extracted brain fractions (APPct detection; left) and representative quantification of Western blots 
(right; result representative of six independent experiments). All data are represented as mean ± SEM.
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numbers of Iba1-positive cells in repopulated APPPS1;TK+/ 
and nonrepopulated APPPS1;TK/ control mice treated 
with Ab9 or isotype control antibodies (Fig. 3, a and b, left). 
As in the previous experiment (Fig. 2 c), there was no obvious 
clustering of the newly recruited cells around cerebral A 
deposits in isotype antibody–treated repopulated mice com-
pared with identically treated nonrepopulated, APPPS1 mice 
(Fig. 3 a, left). Quantification of the number of plaque-associated 
Iba1-positive cells revealed significantly fewer cells per plaque 
(Fig. 3 b, right). Notably, treatment with A-specific antibod-
ies failed to recruit more Iba1-positive cells to the plaques in 
repopulated mice (Fig. 3, a and b, right). Although we observed 
a reduction in the number and area covered by A plaques 
in APPPS1;TK+/ mice harboring peripheral myeloid cells 
(Fig. 3, c and d), this difference was not specific for Ab9 treat-
ment, as isotype-treated APPPS1;TK+/ mice showed a similar 
reduction. Similarly, there was also a reduction in Congo red–
positive plaques in myeloid cell repopulated APPPS1;TK+/ 
mice that did not differ between isotype and Ab9 treatment 
(Fig. 3, e and f ), suggesting that nonspecific stimulation of 
peripheral myeloid cells served to mediate a modestly im-
proved amyloid clearance activity of these cells compared 
with endogenous microglia. In line with these very mild 
changes in plaque burden, there was no major effect on solu-
ble and insoluble as well as total A levels in respective bio-
chemical analyses (Fig. 3 g) and no impact on APP processing, 
as judged by levels of APP, APPCTF, and APPCTF (Fig. 2 h).
Conclusion
Although the presence of peripheral myeloid cells in the CNS 
for 1 mo may simply be too short a timeframe to see a substan-
tial impact of those newly recruited cells on A pathology, in 
this issue, Varvel et al. demonstrate that the extended presence 
of peripheral myeloid cells in the AD-like brain does not suf-
fice to reduce A deposition. Moreover, it is not surprising 
that we did not observe major differences in pathology given 
the fact that peripherally derived myeloid cells failed to associ-
ate with A deposits even in the presence of A-specific anti-
bodies. The mild, but not statistically significant effect on A 
plaque–covered area in repopulated anti-A antibody and 
isotype-treated mice suggests that additional priming of periph-
eral myeloid cells or exposure to A before entering the brain 
may be required to target these cells to A deposits as an essen-
tial prerequisite to induce an efficient reduction in A burden. 
In line with this notion, one has to keep in mind that previ-
ously published studies reporting effects of infiltrating macro-
phages on A pathology used genetic models to either prevent 
recruitment of peripheral myeloid cells, e.g., by deficiency in 
CCR2 (Mildner et al., 2011; Naert and Rivest, 2011), or en-
hance the influx of these cells to the brain (Town et al., 2008). 
In addition to modulating the recruitment to the brain, these 
genetic modifications also impact the activation status of the 
myeloid cell population (including the resident microglia), 
which thus can have a major impact on A pathology by itself, 
irrespective of an increased recruitment of peripheral myeloid 
cells to the CNS. Finally, one can also speculate that A plaques 
are not sufficiently stimulating to engage myeloid cells but that 
these cells rather respond to tissue damage associated with earlier 
stages of plaque development, suggesting that recruitment of pe-
ripheral macrophages to the brain may only be effective at very 
early stages of disease. It will be thus of utmost importance to 
better understand the differences between endogenous microglia 
and peripheral macrophages and to further dissect the specific 
factors involved in attracting myeloid cells to A plaques and 
in efficient clearance of A deposits to develop novel myeloid 
cell–based therapeutic strategies for the treatment of AD.
MATERIALS AND METHODS
Animals and surgery. APPPS1 transgenic mice (Radde et al., 2006) 
were provided by M. Jucker (University of Tübingen, Tübingen, Ger-
many). Male APPPS1+/ mice were crossed to female TK mice (Heppner 
et al., 2005) to generate APPPS1;TK+/ animals and APPPS1;TK/ lit-
termate controls. All animals were housed under specific pathogen–free 
conditions on a 12-h light/dark cycle. Food and water were provided ad 
libitum. All animal experiments were conducted in accordance with ani-
mal welfare acts and were approved by the regional offices for health and 
social services in Berlin (LaGeSo). Microglia depletion was achieved in all 
mice harboring the TK transgene as described previously (Grathwohl et al., 
2009), with modifications. In brief, Cymevene (Roche; 2.5 mg/ml at a 
flow rate of 1 µl/h) was administered icv for 10 d using a mini-osmotic 
pump (model 2001; Alzet). Cymevene treatment was ceased by removal of 
osmotic pumps under isoflurane anesthesia via a small incision in the flank 
without disruption of the cannula. After 10 d of GCV (Cymevene) treat-
ment, APPPS1;TK+/ mice and APPPS1;TK/ control mice received a 
regimen of six intraperitoneal injections of 500 µg of either A1–16-specific 
clone Ab9 antibody (QED Bioscience Inc.) or total nonspecific mouse IgG 
(Equitech Bio) that was purified via protein G column (GE Healthcare). 
All animals were aged 155 d at the start of experiments.
Parabiosis experiments were performed as previously described (Villeda 
et al., 2011), with modifications. In brief, 10 d before surgical joining of mice, 
icv cannula attached to mini-osmotic pumps containing aCSF were implanted 
into the lateral ventricles of wild-type or TK partners. 2 wk after wild-type or 
TK mice were joined with Act.GFP partners, aCSF-containing mini-osmotic 
pumps were exchanged through a small incision in the flank with mini-osmotic 
pumps containing GCV or aCSF. GCV (Roche; 2.5 mg/ml at a flow rate of 
1 µl/h) or aCSF was administered for 10 d, and mice were sacrificed 14 d after 
the cessation of GCV (or aCSF; 24 d after the start of GCV treatment).
Tissue processing. For histological, biochemical, and RNA preparations, 
animals were deeply anesthetized using a ketamine (100 mg/kg) and xylazine 
(10 mg/kg) cocktail and transcardially perfused with sterile PBS, pH 7.4. 
Brains were rapidly removed and divided in half sagittally. The hemisphere 
ipsilateral to the cannula injection site was rapidly frozen in liquid nitrogen 
and stored at 80°C until processing. The rostral portion of the brain hemi-
sphere was processed for biochemical analysis, and the caudal portion was 
used for RNA isolation. The contralateral brain hemisphere was immersed 
in 4% formaldehyde and stored at 4°C for 24 h. Subsequently, the tissue was 
transferred to a 30% sucrose solution until sectioning.
Gene expression analysis. RNA was isolated using TriFast (PEQLAB 
Biotechnology). RNA concentration was determined and purity assessed 
using an Infinite 200 microplate reader (Tecan). 1 µg RNA per sample was 
reverse transcribed to generate cDNA (Quanti Tect Reverse Transcription 
kit; QIAGEN). All qPCR was performed using a 7900HT Fast Real-Time 
PCR System (Applied Biosystems) using cataloged TaqMan assays. Normal-
ization was performed in relation to Gapdh. Specificity of amplification was 
assessed by melting curve analysis. Data analysis was performed manually 
using the Ct method. Positive fold change values between zero and one 
were converted to fold regulation by calculating the reciprocal.
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